Tuesday, November 14, 2017 3:05:45 PM
I Learn From Them, Not Them From Me
If anyone at Anavex deigns to read my Ihub postings about their company and technologies, I'd be honored.
But, should it happen, it's of little consequence. Would be merely a surmising of what one particular AVXL share holder publicly relates about his particular understandings of Anavex technologies and where he, from time to time, thinks they might lead.
Because I'm a biology professional, having written and presented technical papers (none related to neuroscience in any way), and an accomplished biology teacher (retired), I have both the training and desire to make my presentations clear and informative. I attend to good grammar, punctuation, spelling, terminology, and all of the other science writing factors that can keep a presentation of topical text from being regarded as amateurish or inaccurate. As I taught my students, "If you can't say or write it well, accuracy and perception are, at the start, very compromised."
The delight here is the we have a broad and large body of inquisitive, scrutinizing readers who take the time to learn and consider that appears here. Had we not such a fine readership, all of this would be for naught.
And I do so much appreciate the correcting posts from others. How many times have readers discovered inaccuracies or insufficient presentations of mine? I gratefully invite skeptical questions or evidence-based corrections. We are in this together, perceiving and presenting a truly significant change in 21st-century medicine. It is an honor and delight to play a small part in advancing the Anavex revolution.
If anyone at Anavex deigns to read my Ihub postings about their company and technologies, I'd be honored.
But, should it happen, it's of little consequence. Would be merely a surmising of what one particular AVXL share holder publicly relates about his particular understandings of Anavex technologies and where he, from time to time, thinks they might lead.
Because I'm a biology professional, having written and presented technical papers (none related to neuroscience in any way), and an accomplished biology teacher (retired), I have both the training and desire to make my presentations clear and informative. I attend to good grammar, punctuation, spelling, terminology, and all of the other science writing factors that can keep a presentation of topical text from being regarded as amateurish or inaccurate. As I taught my students, "If you can't say or write it well, accuracy and perception are, at the start, very compromised."
The delight here is the we have a broad and large body of inquisitive, scrutinizing readers who take the time to learn and consider that appears here. Had we not such a fine readership, all of this would be for naught.
And I do so much appreciate the correcting posts from others. How many times have readers discovered inaccuracies or insufficient presentations of mine? I gratefully invite skeptical questions or evidence-based corrections. We are in this together, perceiving and presenting a truly significant change in 21st-century medicine. It is an honor and delight to play a small part in advancing the Anavex revolution.
Recent AVXL News
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
